Figure 3 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance Yazar: Marta J. Llorca-Cardenosa (14961612)

Konular:

Figure 4 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance Yazar: Marta J. Llorca-Cardenosa (14961612)

Konular:

Figure 1 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance Yazar: Marta J. Llorca-Cardenosa (14961612)

Konular:

Figure 2 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance Yazar: Marta J. Llorca-Cardenosa (14961612)

Konular:

Figure 5 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance Yazar: Marta J. Llorca-Cardenosa (14961612)

Konular:

Figure 1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models Yazar: Gonzalo Rodriguez-Berriguete (15056057)

Konular:

Figure 2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models Yazar: Gonzalo Rodriguez-Berriguete (15056057)

Konular:

Figure 5 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models Yazar: Gonzalo Rodriguez-Berriguete (15056057)

Konular:

Figure 4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models Yazar: Gonzalo Rodriguez-Berriguete (15056057)

Konular:

Supplementary Table S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models Yazar: Gonzalo Rodriguez-Berriguete (15056057)

Konular:

Figure 3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models Yazar: Gonzalo Rodriguez-Berriguete (15056057)

Konular:

Figure S7 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer Yazar: Li-Li Long (14963775)

Konular:

Figure S5 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer Yazar: Li-Li Long (14963775)

Konular:

Supplementary Table 2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer Yazar: Li-Li Long (14963775)

Konular:

Figure S6 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer Yazar: Li-Li Long (14963775)

Konular:

Supplementary Table 1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer Yazar: Li-Li Long (14963775)

Konular:

Figure S3 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer Yazar: Li-Li Long (14963775)

Konular:

Figure S1 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer Yazar: Li-Li Long (14963775)

Konular:

Figure S2 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer Yazar: Li-Li Long (14963775)

Konular:

Figure S4 from PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer Yazar: Li-Li Long (14963775)

Konular: